Pioneering biotech firm out to raise £8m

Pioneering biotech firm out to raise £8m

Seneca EIS portfolio company and Manchester-based biotech firm Premaitha Health is bidding to raise £8m with a placing of 40 million shares at a price of 20p each.

The company, which has pioneered the IONA non-invasive prenatal test (NIPT) for Down’s Syndrome in unborn children, says the placing is to build on its significant progress since its AIM listing in July last year.

The company wants the cash to accelerate the commercialisation of the IONA test by increasing levels of customer support and boosting its in-house capability. It also want to offer a rental model to selected customers where there are opportunities for commercial leverage and to Increase working capital associated with revenue growth.

Chief executive Dr Stephen Little said: “By raising money now, we are capitalising on our first mover advantage from having the first CE-marked NIPT in vitro diagnostic product on the market. The proceeds of the placing will further strengthen our position, enabling us to develop our product and enhance our customer service offering. Our intention is for the IONA test to become part of the standard of care for all pregnant women, not just those at high risk. This is a very exciting time to be in the NIPT space.”

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.